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Readmissions With Multidrug-Resistant Infection in Patients With
Prior Multidrug Resistant Infection
Jason P. Burnham, MD;1 Jennie H. Kwon, DO, MSCI;1 Margaret A. Olsen, PhD, MPH;1 Hilary M. Babcock, MD, MPH;1
Marin H. Kollef, MD2
objective. To determine incidence of and risk factors for readmissions with multidrug-resistant organism (MDRO) infections among
patients with previous MDRO infection.
design. Retrospective cohort of patients admitted between January 1, 2006, and October 1, 2015.
setting. Barnes-Jewish Hospital, a 1,250-bed academic tertiary referral center in St Louis, Missouri.
methods. We identiﬁed patients with MDROs obtained from the bloodstream, bronchoalveolar lavage (BAL)/bronchial wash, or other
sterile sites. Centers for Disease Control and prevention (CDC) and European CDC deﬁnitions of MDROs were utilized. All readmissions ≤1
year from discharge from the index MDRO hospitalization were evaluated for bloodstream, BAL/bronchial wash, or other sterile site cultures
positive for the same or different MDROs.
results. In total, 4,429 unique patients had a positive culture for an MDRO; 3,453 of these (78.0%) survived the index hospitalization.
Moreover, 2,127 patients (61.6%) were readmitted ≥1 time within a year, for a total of 5,849 readmissions. Furthermore, 512 patients (24.1%)
had the same or a different MDRO isolated from blood, BAL/bronchial wash, or another sterile site during a readmission. Bone marrow
transplant, end-stage renal disease, lymphoma, methicillin-resistant Staphylococcus aureus, or carbapenem-resistant Pseudomonas aeruginosa
during index hospitalization were factors associated with increased risk of having an MDRO isolated during a readmission. MDROs isolated
during readmissions were in the same class of MDRO as the index hospitalization 9%–78% of the time, with variation by index pathogen.
conclusions. Readmissions among patients with MDRO infections are frequent. Various patient and organism factors predispose to
readmission. When readmitted patients had an MDRO, it was often a pathogen in the same class as that isolated during the index admission,
with the exception of Acinetobacter (~9%).
Infect Control Hosp Epidemiol 2018;39:12–19
Hospital readmissions are associated with reduced quality of
life and increased mortality.1–4 An improved understanding of
risk factors for readmission is critical to develop targeted
interventions to prevent readmissions. One major cause of
readmissions is infection, which accounted for as many as
30% of 30-day readmissions.5 In addition, infections during
hospitalization, particularly sepsis, are associated with frequent
30-day readmissions, with estimated rates ranging from 7%
to 43%.6–16
Although multidrug-resistant organism (MDRO) infections
are known to increase the length of stay and healthcare costs,17
their role as a risk factor for readmission has not been
extensively studied. Data suggest that patients with MDRO
infections are at higher risk of readmission, though causes of
readmission in these cohorts are not well deﬁned.18–25
Furthermore, infection as a reason for readmission in sepsis
patients (with or without MDROs) is poorly characterized due
to data limitations and heterogeneity among study designs,
with estimates of readmission rates due to infection ranging
from 20% to 70%.7,10,12,13
Data concerning the rate of readmissions in patients who
had an MDRO infection and the rate of MDRO infections
during readmission in patients with a prior MDRO infection
are lacking. We studied hospitalized patients with MDRO
infections, conﬁrmed by positive cultures from the blood-
stream, bronchoalveolar lavage (BAL)/bronchial wash, or
other sterile site to determine readmission rates and whether
the same or a different MDRO was isolated in sterile site or
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BAL/bronchial wash cultures during a readmission. We did not
use a comparison group of patients with non-MDRO infections
because this population of patients tends to be different from
patients with MDRO infections.26,27 Understanding the rate of
readmission with MDROs in patients with prior MDRO infec-
tions will help guide clinical decision making by improving the
use of targeted empiric antimicrobials in readmitted patients, by
facilitating readmission reduction interventions targeted toward
patients at high readmission risk, and by improving infection
prevention efforts by alerting personnel when patients at high-
risk for MDRO infection are admitted so that proper isolation
precautions can be initiated.
materials and methods
Study Location and Patient Population
This study was conducted at Barnes-Jewish Hospital (BJH), a
1,250-bed academic medical center located in St Louis, Mis-
souri. The study period was January 1, 2006 to October 1,
2015. Hospitalized patients with a positive sterile site or BAL/
bronchial wash culture for Enterobacteriaceae, Enterococcus
spp, Staphylococcus aureus, Pseudomonas aeruginosa, or
Acinetobacter spp were analyzed for eligibility. Antimicrobial
susceptibilities for all pathogens were determined using disc
diffusion methodology. Sterile sites were deﬁned as blood-
stream; pleural, intra-abdominal, pericardial, cerebrospinal,
and synovial ﬂuids; bone marrow; and surgical specimens
collected from lymph nodes; the central nervous system
(CNS), liver, spleen, kidney, pancreas, ovary, or vascular tis-
sue. The Washington University School of Medicine Institu-
tional Review Board approved this study.
Study Design and Data Collection
Utilizing a retrospective cohort study design, the ﬁrst
hospitalization between January 2006 and October 2015
of all patients aged ≥18 years with multidrug-resistant
Enterobacteriaceae, Enterococcus spp, S. aureus, P. aeruginosa,
or Acinetobacter spp isolated from bloodstream, other sterile
sites, or BAL/bronchial wash culture were identiﬁed. Patients
with >1 of these MDROs were considered to have a poly-
microbial infection. Other potentially drug-resistant organ-
isms were not included in the analysis. The primary end points
were any readmission and readmission during which an
MDRO infection occurred. Baseline characteristics, including
age, gender, race, Acute Physiology and Chronic Health Eva-
luation (APACHE) II22 scores (calculated based on clinical
data present during the 24 hours after positive blood cultures
were drawn), Charlson comorbidity index, and medical
comorbidities (based on International Classiﬁcation of Disease,
Ninth Revision, Clinical Modiﬁcation [ICD-9-CM] diagnosis
codes) were obtained. Patients who died during the index
hospitalization or were discharged on hospice were considered
to expire at the time of hospital discharge and were excluded
from analyses related to readmissions.
Deﬁnitions
We assessed 30-day mortality using the BJC Healthcare
Informatics database. Barnes-Jewish Hospital is the main adult
teaching institution for BJC Healthcare, a large integrated
healthcare system of both inpatient and outpatient care. The
system includes 13 hospitals in a compact geographic region
surrounding and including St Louis, Missouri. Barnes-Jewish
Hospital has>50,000 admissions annually, and the BJC system
has >140,000 admissions annually. All index hospitalizations
used to deﬁne the cohort occurred at BJH. Readmissions to
BJH or any other BJC acute-care facility were captured. All
data were derived from the medical informatics database
maintained by the Center for Clinical Excellence, BJC
HealthCare. To be categorized as having an MDRO during a
readmission, blood, BAL/bronchial wash, or sterile-site
cultures positive for an MDRO could be obtained any time
during the readmission. Patient death dates are included in the
informatics database. For patients with <1 year of follow-up
care at BJC HealthCare after index hospitalization, the Social
Security Death Index (SSDI) was used to identify patient
deaths. Patients without follow-up in the BJC system and who
were not in the SSDI were considered lost to follow-up on their
last date of care in a BJC facility. Index MDRO admission
survivors were considered censored at their date of death or
loss to follow-up.
Deﬁning MDROs
We utilized multiple deﬁnitions of drug resistance as outlined by
the Centers for Disease Control and Prevention (CDC) and
European CDC (Supplemental Table 1).28–30 Any Enterobacter-
iaceae was presumed to be an extended-spectrum β-lactamase
(ESBL) producer if ceftriaxone or ceftazidime was intermediate
or resistant. Patients were considered to have a vancomycin
intermediate S. aureus (VISA) infection if S. aureus was isolated
in culture and was determined to have a vancomycin
minimum inhibitory concentration (MIC) of 4 or 8 µg/mL, in
accordance with Clinical and Laboratory Standards Institute
recommendations.31
Statistical Analysis
Comparisons between index MDRO admission survivors and
nonsurvivors were performed using the χ2 or the Fisher exact
test for categorical values and using the Student t test or Mann-
Whitney U test for continuous variables. Readmissions by
index hospitalization pathogen group were analyzed using
Kaplan-Meier curves. Continuous variables were reported as
means with standard deviations or medians and interquartile
ranges (IQRs). Categorical data were expressed as frequencies.
In bivariate analysis, the relative risk of in-hospital mortality or
discharge on hospice from index MDRO hospitalization was
calculated using drug-resistant S. aureus as the reference group
because it was the largest group and had the lowest mortality.
For bivariate analysis of variables associated with readmissions
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or readmissions with an MDRO, a Cox proportional hazards
model was used. The proportional hazards assumption was
checked graphically using a log-log survival plot. A P value of
< .05 was considered signiﬁcant in all analyses. Multivariate
Cox proportional hazards models were used to determine risk
factors for readmission overall and risk factors for a readmission
during which an MDRO was isolated. Factors associated with
mortality in bivariate analysis (P < .20) were entered into a Cox
proportional hazards model to determine hazard ratios (HRs)
for readmission. Nonsigniﬁcant predictors were retained in
ﬁnal models if their P value was < .20 in bivariate analysis. All
variables entered into the model were assessed for collinearity,
and clinically plausible interaction terms were tested in the
model (Supplemental Table 2). Model diagnostics included
plotting of DFBETAs to detect inﬂuential cases and martingale
residuals for a residuals pattern. Linearity of the Charlson
comorbidity index for the outcome was conﬁrmed prior to
model entry. All analyses were conducted with SPSS version 24
software (IBM, Armonk, NY).
results
A total of 4,429 patients with MDROs from sterile sites or BAL/
bronchial wash cultures were identiﬁed, and 976 patients
(22.0%) died during the index hospitalization or were discharged
to hospice. Nonsurvivors were older and had more underlying
comorbidities and higher APACHE-II scores than survivors
(Supplemental Table 3). In bivariate analysis, nonsurvivors were
more likely to have any drug-resistant Enterococcus,Acinetobacter,
or P. aeruginosa than survivors and less likely to have a drug-
resistant S. aureus infection (Supplemental Table 3). Patients with
any drug-resistant Acinetobacter had the highest index hospitali-
zation mortality (n = 44, 41.1%), with a relative risk (RR) of
death of 2.45 compared to patients with drug-resistant S. aureus
(P < .0001) (Supplemental Table 4). There were signiﬁcant
differences in the APACHE-II scores among patients in the
different index pathogen groups (P < .001) (Supplemental
Table 5). Additional differences in patient characteristics among
index pathogen groups are shown in Supplemental Table 5.
Comorbidities, age, gender, ICU utilization, length of
hospital stay, and the site from which an MDRO was isolated
were all signiﬁcantly different between groups (Supplemental
Table 5).
Among the 3,453 index MDRO hospitalization survivors,
1,121 (32.5%) were readmitted at least once within 30 days after
discharge from the index hospitalization, and 2,127 (61.6%)
were readmitted within 1 year. These 2,127 patients had a total
of 5,849 readmissions within 1 year, with a median of 2 read-
missions per patient (IQR, 1–4; range, 1–28). The median time
to ﬁrst readmission was 26.9 days (IQR, 9.9–76.9). Survivors
infected with drug-resistant Acinetobacter were least likely to be
readmitted, and those infected with drug-resistant Enterococcus
most likely to be readmitted (Figure 1) (P < .001). Differences
in baseline characteristics between survivors readmitted within
1 year and those who were not are shown in Table 1.
Of the survivors who were not readmitted within 1 year, 500
(14.5%) were lost to follow-up. In bivariate analysis, patients
lost to follow-up were signiﬁcantly (P < .05) more likely to
have cardiovascular disease, chronic respiratory failure, be
older, have had an ICU stay during index hospitalization, and
be discharged to a skilled nursing facility (SNF), a long-term
acute-care hospital (LTACH), or a nursing home (NH) (data
not shown).
In a multivariate Cox proportional hazards model of
survivors, any ICU stay during the index hospitalization was
associated with a reduced HR for readmission (HR, 0.88) as
was having a positive bronchoscopy culture (HR, 0.83) or
infection with a drug-resistant Acinetobacter (HR, 0.71).
Factors associated with increased risk of readmission were
cirrhosis (HR, 1.24), leukemia (HR, 1.44), Charlson comor-
bidity index (HR, 1.06 per unit increase), VRE (HR, 1.15), and
carbapenem-resistant P. aeruginosa during index hospitaliza-
tion (HR, 1.40) (Table 2).
Of the 2,127 patients with at least 1 readmission within
1 year, 512 (24.1%) had an MDRO isolated during at least
1 readmission. The median time to a new positive MDRO
culture after discharge from the index hospitalization was
61.9 days (IQR, 24.3–140.6). Patients with index drug-
resistant Enterobacteriaceae were the least likely and patients
with index drug-resistant Acinetobacter were the most likely to
be readmitted with another MDRO infection (P = .001)
(Figure 2). Differences in baseline characteristics between
readmitted patients with and without another MDRO during
readmission are shown in Supplemental Table 6. Patients with
readmissions that did not end prior to 365 days after index
hospitalization discharge could have hadMDROs isolated after
ﬁgure 1. Time to ﬁrst readmission by index multidrug-resistant
organism (MDRO) hospitalization pathogen type. Patients censored
at death or loss to follow-up. Log-rank, 44.340; P < .001; 5° of
freedom. All index pathogens are drug resistant.
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365 days that were not captured by this study, though this
involved only 14 patients (0.7%).
We performed a multivariate Cox proportional hazards
model comparing patients with anMDRO during a readmission
to patients without any MDROs during readmission. Bone
marrow transplant (HR, 1.79), end-stage renal disease (HR,
1.43), lymphoma (HR, 1.49), methicillin-resistant S. aureus
(MRSA) during index hospitalization (HR, 1.29), and
carbapenem-resistant P. aeruginosa during index hospitalization
(HR, 1.99) were all associated with a signiﬁcantly increased risk
of having an MDRO isolated during a readmission (Table 3).
In patients who had an MDRO isolated during readmission,
the readmission MDRO was in the same pathogen class as the
index hospitalization MDRO 68%–80% of the time, with 1
exception. For patients with drug-resistant Acinetobacter
during index hospitalization, only 9.1% had drug-resistant
Acinetobacter isolated during a readmission (Table 4), though
numbers were small in this group. Discordant results between
table 1. Comparison of Survivors of the Index MDRO Hospitalization Readmitted Within 1 Year to Those
Who Were Not Readmitted Within 1 Year After Discharge From the Index MDRO Hospitalization
Index Admission Characteristics
No. (%) of Survivors Not
Readmitted (N= 1,326)a
No. (%) of Survivors
Any Readmission (N= 2,127)a P Valueb
Age, y (± SD) 57.8±17.0 56.7± 15.8 .152
Gender, male 771 (58.1) 1230 (57.8) .653
Ethnicity, white 919 (69.3) 1348 (63.4) .078
Any ICU stay 734 (55.4) 966 (45.4) .002
Bone marrow transplant 19 (1.4) 74 (3.5) <.001
Solid organ transplant 56 (4.2) 126 (5.9) .314
Cardiovascular disease 773 (58.3) 1209 (56.8) .230
Congestive heart failure 311 (23.5) 488 (22.9) .006
Chronic respiratory failure 394 (29.7) 561 (26.4) .030
Diabetes mellitus 453 (34.2) 758 (35.6) .293
Chronic kidney disease 263 (19.8) 506 (23.8) <.001
End-stage renal disease 126 (9.5) 274 (12.9) .003
Solid organ malignancy 270 (20.4) 471 (22.1) .014
Leukemia 83 (6.3) 274 (12.9) <.001
Lymphoma 59 (4.4) 120 (5.6) .091
Cirrhosis 78 (5.9) 149 (7.0) .002
Charlson comorbidity score (IQR) 3 (1–5) 4 (2–6) <.001
APACHE-II score (± SD) 11.4±5.2 11.2± 5.0 .535
Culture source
Blood 908 (68.5) 1565 (73.6) .001
Bronchial wash/BAL 246 (18.6) 282 (13.3) <.001
Other sterile site 270 (20.4) 422 (19.8) .709
> 1 site 97 (7.3) 138 (6.5) .348
Index drug-resistant organismc
Staphylococcus aureus 588 (44.3) 873 (41.0) .056
Enterococcus 181 (13.7) 402 (18.9) <.001
Enterobacteriaceae 403 (30.4) 605 (28.4) .221
Acinetobacter 29 (2.2) 34 (1.6) .209
Pseudomonas aeruginosa 55 (4.1) 95 (4.5) .655
Polymicrobial 70 (5.3) 118 (5.5) .735
Index discharge disposition
Left hospital against medical advice 14 (1.1) 9 (0.4) .079
Home 682 (51.4) 1301 (61.2) .486
SNF/LTACH/Rehab/NH 586 (44.2) 783 (36.8) .959
Other hospital 44 (3.3) 34 (1.6) .235
Index LOS, d (IQR) 15.1 (7.8–29.8) 13.9 (7.0–30.1) .147
NOTE. MDRO, multidrug-resistant organism; APACHE-II, Acute Physiology and Chronic Health Evaluation; BAL,
bronchoalveolar lavage; ICU, intensive care unit; IQR, interquartile range; LTACH, long-term acute-care hospital;
LOS, length of stay; NH, nursing home; SNF, skilled nursing facility; SD, standard deviation.
aUnless otherwise speciﬁed.
bP values were obtained using univariate Cox regression.
cDrug resistance was deﬁned according to the deﬁnitions in Supplemental Table 1.
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index and readmission cultures are shown in Supplemental
Figure 1. To investigate why Acinetobacter was an outlier, we
analyzed baseline characteristics of the cohort stratiﬁed by
index hospitalization pathogen group. The proportion of
patients who died or were discharged on hospice was
signiﬁcantly different between index pathogens, with Acineto-
bacter patients having the highest rate of death or discharge on
hospice (P < .001) (Supplemental Table 5). Drug-resistant
Acinetobacter patients were equally likely to have no bacterial
cultures collected during readmissions (17.6%) and to be lost
to follow-up (14.3%) as patients from other pathogen groups
(data not shown).
discussion
All-cause readmissions within 1 year after index MDRO hos-
pitalization were frequent in this study. The 30-day and 1-year
all-cause readmission rates were higher than in previously
published studies examining readmissions after systemic
infections, suggesting a higher readmission rate in patients
with MDRO infections.6–10,12–15,20 Although data are limited,
other studies suggest rates of readmission for MDROs similar
to those in our study (32%).32 In the present study, the rate of
readmission differed by type of MDRO isolated during the
index hospitalization. Surviving patients with drug-resistant
Acinetobacter were least likely to be readmitted within 1 year,
and patients with drug-resistant Enterococcus were the most
likely to be readmitted within 1 year. Independent risk factors
for readmission within 1 year included certain comorbidities
and certain pathogens (Table 2). These results suggest that
patient and pathogen factors both contribute to all-cause
readmission risk. Risk factors for mortality during the index
MDRO hospitalization were less common as risk factors for
readmission, which may explain why certain factors such as an
ICU stay, which are associated with an increased risk of death,
were thus associated with a reduced risk of readmission.
Almost 25% of patients readmitted within 1 year after an
MDRO infection had an MDRO isolated during a readmission.
ﬁgure 2. Time to ﬁrst positive multidrug-resistant organism
(MDRO) culture within 1 year of index MDRO hospitalization by
index hospitalization pathogen. All index pathogens are drug
resistant. Log-rank, 21.220; 5° of freedom; P= .001. Note y-axis
scale from 0.6 to 1.0.
table 2. Index MDRO Hospitalization Factors Associated With
Any Readmission Within 1 Year in a Multivariable Cox Proportional
Hazards Modela
Factors From Index MDRO
Hospitalizationb HR (95% CI) P Value
Leukemia 1.44 (1.24–1.68) <.001
Carbapenem-resistant Pseudomonas 1.39 (1.12–1.72) .002
Cirrhosis 1.23 (1.04–1.47) .018
Vancomycin-resistant Enterococci 1.15 (1.01–1.32) .041
Charlson comorbidity index 1.06 (1.04–1.08) <.001
ICU stay 0.88 (0.80–0.97) .011
Positive bronchoscopy culture 0.84 (0.70–0.99) .031
Drug-resistant Acinetobacter 0.70 (0.52–0.95) .027
NOTE. MDRO, multidrug-resistant organism; CI, conﬁdence interval;
HR, hazard ratio; ICU, intensive care unit; ESBL, extended-spectrum
β-lactamase; MRSA, methicillin-resistant Staphylococcus aureus.
aPopulation = survivors of index hospitalization.
bOther variables included in the model that were not signiﬁcant: age,
ethnicity, receipt of a bone marrow transplant, congestive heart fail-
ure, cirrhosis, chronic kidney disease, chronic respiratory failure, end-
stage renal disease, lymphoma, solid organ malignancy, blood culture
with an MDRO, ESBL Enterobacteriaceae, MRSA, and length of stay.
table 3. Index MDRO Hospitalization Factors Associated With
Readmission (Within 1 Year) in Which an MDRO Was Isolated
Compared to Readmitted Patients Without MDROsa
Factor From Index MDRO
Hospitalizationb HR (95% CI) P Value
Carbapenem-resistant Pseudomonas 1.98 (1.35–2.90) <.001
MRSA 1.31 (1.03–1.68) .047
Bone marrow transplant 1.80 (1.14–2.84) .012
Lymphoma 1.48 (1.05–2.09) .022
End-stage renal disease 1.42 (1.05–1.92) .020
NOTE. MDRO, multidrug-resistant organism; HR, hazard ratio; CI,
conﬁdence interval; MRSA, methicillin-resistant Staphylococcus
aureus; VRE, vancomycin-resistant Enterococcus.
aMultivariable Cox proportional hazards model.
bOther variables included in the model that were not signiﬁcant:
ethnicity, sex, cardiovascular disease, congestive heart failure, chronic
kidney disease, diabetes, leukemia, solid organ malignancy, Charlson
comorbidity index, positive blood culture MDRO, positive other
sterile site MDRO culture, VRE, drug-resistant Acinetobacter,
discharge disposition, and index hospital length of stay.
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The rate of readmissions during which an MDRO was isolated
differed by the MDRO isolated at the index hospitalization. Few
studies are available for comparison, but it appears that our
readmission rate for MDRO patients may be similar to those of
other cohorts.32,33 Whether drug resistance itself is a risk factor
for readmission is not clear and is not addressed by this study.
Previous work has shown higher rates of readmission for
antibiotic-resistant (vs antibiotic-susceptible) pathogens.18,32 A
history ofMRSA, VRE, or an ESBL gram-negative organismwas
associated with 1.6-fold increased odds for readmission in one
cohort.34 Another study showed no difference in readmission
rates between methicillin-sensitive and MRSA when adjusting
for other comorbidities and severity of illness.35 In the context
of our study, it is important to recognize that our patients were
likely at high risk of readmission due to their high baseline
severity of illness and their infections. Because we did not
include a group of patients with non-MDRO infections as a
comparator, the impact of drug resistance on readmission rates
cannot be deduced from the present study. Multicenter studies
will likely be required to address the impact of drug resistance
on readmission rates and will need to consider factors such as
the adequacy of source control and appropriateness of therapy
in calculation of readmission risk.
In the present study, independent risk factors for MDRO
isolation during a readmission included comorbidities (receipt
of BMT, ESRD, lymphoma) and certain pathogens during the
index hospitalization (VRE, MRSA, and carbapenem-resistant
P. aeruginosa) compared with patients who were readmitted
but had no MDROs isolated. These results suggest that patient
and pathogen factors both contribute to the risk of read-
mission with an MDRO. In addition, we found that the
MDRO isolated during a readmission is in the same class as the
index hospitalization MDRO 67%–78% of the time, except for
Acinetobacter (~9%), though numbers were small in the
Acinetobacter group. Recognizing the heterogeneity of MDROs
that occur during readmissions will help to better deﬁne
patients in need of broad-spectrum empiric antimicrobial
therapy at readmission.
Our study has several limitations. The retrospective design
of the study makes it difﬁcult to elucidate possible confounders
that could have biased the outcome measures. This was a
single-center study, and results may not be generalizable to
other centers. However, the high rates of readmission and
readmissions during which MDROs were isolated should be
applicable to other tertiary-care referral centers with similar
patient case mixes. We relied on clinical cultures to deﬁne
MDRO recurrence, which likely underestimates the actual rate
of readmissions with MDROs because we did not capture
surveillance cultures that might identify colonization. It is
possible that patients received antibiotics prior to having
cultures collected during readmissions, which would also
lower the apparent MDRO recurrence rate. As diagnostic
microbiology methods continue to improve, the incidence of
culture-negative sepsis will likely decrease, making it easier to
more accurately assess populations at highest risk of read-
missions with an MDRO recurrence.
We were limited by a lack of data on non-MDRO pathogens
with which to compare readmission rates, but previous work
has shown that patients acquiring MDRO infections are
fundamentally different than patients with non-MDRO
infections.26,27 Therefore, it was more important to compare
patients with different types of MDROs rather than compare
patients with non-MDRO infections to those with drug-
resistant infections due to the same organism.
Another limitation of our study is loss to follow-up. Some
patients may have gone to a facility outside of the BJC Health-
care network where we were unable to capture their MDRO
recurrence status. Patients censored at loss to follow-up were
more likely to be discharged to a SNF, LTACH, or NH, where
the local physicians could have diagnosed and treated MDRO
infections without our knowledge. In addition, patients lost to
follow-up were more likely to have had an ICU stay during their
index MDRO hospitalization, which could explain why having
an ICU stay was associated with a reduced hazard ratio for
readmission. The study was also limited by a lack of treatment
data to assess the appropriateness of antibiotic therapy as a
potential reason for readmissions in this cohort.
In conclusion, all-cause readmissions and readmissions dur-
ing which an MDRO was isolated are common among patients
with MDRO infections. Patient characteristics and pathogen
type both contribute to the risk of readmissions overall and
readmissions during which an MDRO was isolated. By
table 4. Patient Survival, Readmission, and MDRO Recurrence Characteristics by Index Hospitalization Pathogen Group
Index Drug-Resistant
Pathogen







(With Any MDRO) With an Isolate From
the Same Class as the Index
Staphylococcus aureus 1,461 (83.3) 873 (59.8) 216 (24.7) 169 (78.2)
Enterococcus 583 (68.6) 402 (69.0) 102 (27.1) 73 (71.6)
Enterobacteriaceae 1,008 (82.4) 605 (60.0) 110 (18.2) 78 (70.9)
Acinetobacter 63 (58.9) 34 (54.0) 11 (32.4) 1 (9.1)
Pseudomonas 150 (75.0) 95 (63.3) 31 (32.6) 21 (67.7)
Polymicrobial 188 (66.3) 118 (62.8) 35 (29.7)
NOTE. MDRO, multidrug-resistant organism.
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analyzing readmissions withMDROs, we aimed to elucidate risk
factors for readmission in this population, to provide opportu-
nities for targeted interventions to potentially prevent read-
missions, and to help deﬁne the risk of MDRO infection during
readmission so that infection prevention programs can initiate
the proper isolation precautions and reduce the spread of
MDROs within hospitals. In addition, our research gives pro-
viders guidance about which patients are most likely to need
broad-spectrum antimicrobials when they are readmitted, based
on the knowledge that MDRO recurrence is high in this
population.
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